spacer
home > ebr > winter 2018 > particle acceleration
PUBLICATIONS
European Biopharmaceutical Review

Particle Acceleration

First established more than 200 years ago as a defence against infectious diseases, vaccine development proliferated in the mid-20th century as researchers began to fully exploit the use of inactive and attenuated disease strains. The key to a successful vaccine is to identify and isolate an agent that can be safely administered to the patient to trigger a sufficiently protective immune response, without causing a full-blown illness. For some diseases, a completely inactive strain performs this function, while for others attenuation or modification of an active strain – often by passaging through animal embryos – provides an answer.

More recently, newer vaccine technologies have been adopted to tackle diseases not amenable to these traditional approaches. Today’s researchers routinely deploy subunit and conjugate vaccines – both of which contain only fractions of the pathogen for which they provide protection – and viruslike particles (VLPs). These ‘trick’ the body into an immune response by precisely mimicking the morphology and outer surface of the live virus, but lack the genetic material needed to reproduce, thereby offering the same levels of safety as inactive vaccines. In vivo, such VLPs must be effectively indistinguishable from the active pathogen, so their structure is critical.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Dave Stuart is Medical Research Council Professor of structural biology at the University of Oxford, UK, and joint-head of the division of structural biology at the Department of Clinical Medicine. He was appointed Director of Life Sciences at Diamond Light Source in 2008. Dave’s principal research interests include the structure of viruses and viral proteins, as well as cellular proteins, especially those that interact with viruses.
spacer
Diamond Light Source
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. This latest extension includes grants from MJFF to support two projects:
More info >>

White Papers

Case Study: Emerade® Auto-Injector

SHL Group

The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >>

 
Industry Events

T3: Trials, Tech and Transformation

30-31 May 2018, Raleigh Convention Center, Raleigh, NC

T3 is back for 2018 to provide you with the latest updates and top tips from across the clinical trials landscape. Connecting leading experts, influencers and innovators from pharma, biotech, CROs, patient advocacy groups, academia and beyond, T3 is themeeting place for all stakeholders to voice their questions, connect with peers, and get direct feedback from an expert speaker line-up.And this year, we're in Raleigh.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement